MedTrace Logo

Lopinavir/Ritonavir in PLWH With High-Grade AIN

NCT05334004 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-05-15

No results posted yet for this study

Summary

This study is being done to assess the safety of lopinavir/ritonavir in patients with PLWH with AIN. 30 participants will be recruited and can expect to be on active study for approximately 3 months and long term follow up for 40 weeks.

Conditions

  • High-Grade Anal Intraepithelial Neoplasia

Interventions

DRUG

Lopinavir / Ritonavir

Human Immunodeficiency Virus (HIV) antiviral, given via suppository

Sponsors & Collaborators

  • Wisconsin Partnership Program

    collaborator OTHER

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Evie Carchman, MD, FACS · University of Wisconsin, Madison

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-19
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05334004 on ClinicalTrials.gov